Priyank Patel, MD

Hematology/Medical Oncology - Carle Cancer Center; Clinical Assistant Professor of Medicine, CICOM, University of Illinois at Urbana-Champaign. Tweets = own.

[Papa Heme @Papa_Heme]

Come join Nevada's first BMT/cell therapy!

We are already super successful. We need another doc.

I can only last so long doing Q2week call! We are helping patients in great need.

I have never asked for a retweet, but colleagues please retweet.

https://t.co/H9Xu1MdwSa

[Priyank Patel, MD @stellardoc1]

@richardbuka @BrJHaem Very practical data for community hematologists. Thanks for answering this question.

[National Board of Physicians and Surgeons @InfoNbpas]

NBPAS PRESS RELEASE : "We urge every physician who has been harmed by ABMS MOC to speak now, speak loudly, and spread the word to every physician you know." - Dr. Paul Teirstein
https://t.co/EhgDw2ox6w

@doctorwes @AaronGoodman33 @MartyMakary @VPrasadMDMPH @VincentRK

[Priyank Patel, MD @stellardoc1]

@AaronGoodman33 Clinical trialists do not see the volume of patients community oncologists see. Clinical skills that have developed over years have their own intrinsic immeasurable value. This is not reflected by the thickness of the CV. We love taking care of patients too.

[National Board of Physicians and Surgeons @InfoNbpas]

BREAKING: FTC and DOJ Antitrust Division opened new portal to hear about the monopolies controlling healthcare and stifling competition. Please take a minute and make them aware of the ABMS monopoly!
@doctorwes @AaronGoodman33 @chadinabhan @MartyMakary @VPrasadMDMPH

Submit a Healthcare Competition Complaint
https://t.co/nKlNd7stjN

[Vincent Rajkumar @VincentRK]

Yes. I decided last week to STOP doing MOC for internal medicine and Medical Oncology.

[Priyank Patel, MD @stellardoc1]

@VincentRK Same with abiraterone on Cost Plus. Much cheaper. No need to do coverage gimmicks. 30 count of 250 mg costs $33.50. Just take it with low fat food.
But… available at GoodRx pharmacies for average price of just $2700.00 per month.

[Priyank Patel, MD @stellardoc1]

@batraatulmd @JCO_ASCO @TuttsAkhil @atul1_p @SameerBak Simple, effective and practice changing. Gotta love some of these trials from Indian colleagues! Congratulations @batraatulmd , strong work.

[Priyank Patel, MD @stellardoc1]

I long for that day @mcuban will get generic for lenalidomide on @costplusdrugs. Lenalidomide (Revlimid) pricing is a racket and an open example of white collar corruption.

[Dr Amol Akhade @SuyogCancer]

How price per pill of lenalidomide kept on rising in USA 🇺🇸.
22 times the price was raised . From 215 $ in 2005 to 763 $ in 2020.
And what all Tricks of the trade played by Celgene to keep the price high and block the entry of generics. And when most of the research was funded by government aided grants. 🤫
This is shocking and insane.
I don't know how health economy in USA 🇺🇸 is able to sustain this and will it collapse on one fine day ?? 🤔

And just to compare the same pill is available for close 2 to 3 $ in India 🇮🇳 @JCOOP_ASCO @asco @5_utr @AaronGoodman33 @ManniMD1 @VPrasadMDMPH @Dr_AmerZeidan @dr_yakupergun @DrYukselUrun @NicoleKuderer @gary_lyman

[Priyank Patel, MD @stellardoc1]

@zen228 @MrinalPatnaik @HemOncFellows I have watched such cases if no infection. If infection then for sure growth factor support. If patient or MD anxious then too growth factors support.

[Priyank Patel, MD @stellardoc1]

@ErikaHamilton9 Check East Asian grocery stores. I get it from there.

[Priyank Patel, MD @stellardoc1]

How screwed up you career needs to be for you to sell your soul to Evicore and be a P2P for insurance industry?

[Priyank Patel, MD @stellardoc1]

@ManniMD1 @End_myeloma I sometimes think of biochemically recurrent prostate cancer. We do treat some patients when PSAdt is short and based on Gleason and other factors but many patients are monitored for years before even pulling the trigger to start ADT.

[Oncology Brothers @OncBrothers]

What just happened? 5 new 💊/indications ✅ by @FDAOncology in the last 10 days. As #CommunityOncologists, we need to know them all:

1.#Fruquintinib in refractory mCRC, mPFS 3.7mos vs 1.8mos

2.#Pembrolizumab (+Chemo) in 1L mGEJ/Gastric Ca, mOS 12.9mos Vs 11.5mos

3.#Capivasertib (+Fulvestrant) in PIK3CA/AKT1/PTEN +ve metastatic HR+ Breast Ca after >1 endocrine Rx, mPFS 7.2mos Vs 3.6mos

4. #Repotrectinib in 1L mNSCLC ROS1 +ve, ORR 79% and mDoR 34mos

5.#Enzalutamide (+/- ADT) in non-Mets HSPC, 5yr MFS: 87.3% (combo) Vs 80% (Enza monotherapy) Vs 71.4% (ADT alone)

#bcsm #crcsm #OncTwitter #lcsm #MedEd #OncEd #gusm #gism @OncoAlert @ThanksCancer @neerajaiims

[Priyank Patel, MD @stellardoc1]

Interesting discussion about how a large whale swallows a smaller fish. All for profit. Patients loose. Large hospitals do not provide better oncology care but surely do cost the system a lot more money. Govt should actively think of preventing healthcare consolidation.

[Priyank Patel, MD @stellardoc1]

@ManniMD1 I question whether this protocol is even considered to be ethical. I don’t know but this sure is stretching the limits.

[Priyank Patel, MD @stellardoc1]

@eliojabraMD You’re welcome @eliojabraMD. You will do great with your residency and fellowship. It is very rewarding to teach hardworking, bright and ambitious folks like you.

[Priyank Patel, MD @stellardoc1]

@SuyogCancer @Prasshmehta @myESMO @OncoAlert @montypal As always, devil is in the details

[Priyank Patel, MD @stellardoc1]

@ASCOPres @neerajaiims @ASCO No survey yet anywhere